Editas Medicine appoints Dan Ory as chief medical officer - EDIT News | RalliesEditas Medicine appoints Dan Ory as chief medical officer
E
EDIT• Dan Ory named chief medical officer
- Editas Medicine appointed Dan Ory as chief medical officer, effective today.
- Ory will lead clinical development as Editas advances EDIT-401, an in vivo gene-editing candidate for hyperlipidemia, toward the clinic.
- He previously served as chief medical officer at Arbor Biotechnologies, overseeing a global clinical trial for an in vivo gene-editing program.
- Earlier roles include chief medical officer at Casma Therapeutics, leading clinical programs in rare genetic and neurodegenerative diseases.
- Ory spent more than two decades at Washington University School of Medicine, researching cholesterol metabolism and Niemann-Pick disease type C.
XLV
•
